- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Head and neck cancer, the sixth most common cancer in the world, has remained one of the more difficult malignancies to treat, and even when treatment is successful, patients suffer severely from the available therapies. Now, researchers at the University of Michigan have developed a tumor-targeted nanoparticle that delivers high doses of anticancer agents directly to head and neck tumors. Tests in animals have shown that this novel formulation increases survival while triggering fewer side effects.
Reporting its work in the Journal of Oral and Maxillofacial Surgery, a team led by James R. Baker, Jr., created a spherical polymeric nanoparticle known as a dendrimer to deliver the drug methotrexate to head and neck tumors. To target the nanoparticle to those tumors, the investigators decorated the nanoparticle's surface with folic acid. Many tumors, but few healthy cells, produce excessive amounts of a folic acid receptor on their surfaces. Dr. Baker and his colleagues pioneered the use of dendrimers as targeted drug-delivery vehicles with funding from the National Cancer Institute's Alliance for Nanotechnology in Cancer.
The researchers tested their dendrimer-based formulation in three different groups of mice. The control group had tumors grown from human head and neck tumors that did not produce the folic acid receptor. The two experimental groups had tumors grown from human head and neck tumors that expressed moderate and high levels of the folic acid receptor. Mice receiving the equivalent of three times the normally lethal dose of methotrexate, delivered on the dendrimer nanoparticle experienced none of the weight loss normally associated with methotrexate therapy. More importantly, dendrimer-delivered therapy produced marked gains in therapeutic response even in the mice whose tumors produced only moderate levels of folic acid receptor.
About The National Cancer Institute (NCI)
The NCI Alliance for Nanotechnology in Cancer is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat, and prevent cancer. Through its programs and initiatives, the Alliance is committed to building a community of researchers dedicated to using nanotechnology to advance the fight against cancer.
As part of the Center for Strategic Scientific Initiatives, the Alliance for Nanotechnology in Cancer works in concert with other NCI advanced technology initiatives to provide the scientific foundation and team science that is required to transform cancer research and care.
For more information, please click here
National Cancer Institute
Center for Strategic Scientific Initiatives
NCI Office of Cancer Nanotechnology Research (OCNR)
Building 31, Room 10A52
31 Center Drive, MSC 2580
Bethesda, MD 20892-2580
Telephone: (301) 451-8983
Copyright © The National Cancer Institute (NCI)If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Better living through pressure: Functional nanomaterials made easy April 19th, 2017
Nanotubes that build themselves April 14th, 2017